This article is for educational purposes only and is not intended as medical advice.
For Floridians living with Crohn’s disease, medical marijuana may be one treatment option available under state law.
Crohn’s disease is a chronic inflammatory bowel disease (IBD) that affects millions of people worldwide. It causes inflammation anywhere along the gastrointestinal tract and may result in abdominal pain, persistent diarrhea, fatigue, weight loss, malnutrition, and a significantly reduced quality of life. Although there is currently no cure, advances in conventional medicine and supportive therapies continue to improve symptom management and patient outcomes.
Crohn’s disease is specifically listed as a qualifying medical condition under Florida’s Medical Marijuana Use Program, allowing eligible patients who are diagnosed by a qualified physician to obtain a Medical Marijuana Use Registry Identification Card and purchase medical cannabis from a licensed Medical Marijuana Treatment Center (MMTC).
Physicians may also certify patients with medical conditions that are of the same kind or class as the listed qualifying conditions.
Among supportive therapies, medical marijuana has received increasing attention for its potential to relieve symptoms associated with Crohn’s disease. But what does the scientific evidence actually show?
Clinical Evidence
Interest in cannabis as a treatment for Crohn’s disease has grown over the past decade, leading to several clinical trials and systematic reviews.
Naftali et al. (2013): THC-Rich Cannabis
Dr. Timna Naftali, a pioneer in researching cannabinoids for Inflammatory Bowel Disease (IBD), has conducted a series of progressively advanced studies on the topic.
One of the first randomized, double-blind, placebo-controlled clinical trials was conducted by Naftali et al. and published in Clinical Gastroenterology and Hepatology in 2013.
The study enrolled 21 patients with treatment-resistant Crohn’s disease. Patients who received THC-rich cannabis experienced:
– Significant improvement in Crohn’s disease symptoms
– Reduced abdominal pain
– Improved appetite
– Better sleep quality
– Improved overall quality of life
– Clinical remission in several participants
Although the results were encouraging, researchers emphasized that the study was small and did not demonstrate a significant reduction in intestinal inflammation.
Naftali et al. (2017): CBD-Rich Cannabis Oil
In a follow-up randomized, placebo-controlled study, the researchers evaluated CBD-rich cannabis oil.
Unlike the earlier THC trial, CBD-rich cannabis did not significantly improve disease activity or induce remission, suggesting that CBD alone may not provide the same therapeutic effects observed with THC-containing products.
Systematic Reviews
The 2019 Cochrane Database of Systematic Reviews evaluated all available randomized clinical trials involving cannabis and Crohn’s disease.
The reviewers concluded that:
– Medical cannabis may improve symptoms and quality of life.
– Evidence remains limited because only a few small clinical trials have been completed.
– There is insufficient evidence that cannabis reduces intestinal inflammation, induces remission, or alters the progression of Crohn’s disease.
Controlled Trials: Follow-up double-blind, placebo-controlled trials (such as her work on ulcerative colitis published around 2021) provided rigorous data showing THC-rich cannabis improved clinical outcomes compared to placebos, though underlining the distinction between symptom relief and direct anti-inflammatory action. National Library of Medicine
A 2025 systematic review and meta-analysis published in the Irish Journal of Medical Science reached similar conclusions, finding improvements in pain, appetite, sleep, and quality of life while emphasizing the need for larger, high-quality clinical trials before firm recommendations can be made.
The Bottom Line
Medical marijuana shows promise as a supportive therapy for relieving symptoms of Crohn’s disease, particularly pain, nausea, appetite loss, and sleep problems. Researchers continue to study which cannabinoid formulations, dosages, and delivery methods may provide the greatest benefit while minimizing adverse effects.
What This Means for Florida Patients
Because Crohn’s disease is a qualifying condition in Florida, eligible patients may discuss medical marijuana with a qualified physician as part of their treatment plan.
However, current scientific evidence indicates that medical cannabis should be viewed primarily as a symptom-management therapy, not as a cure or a replacement for conventional treatments such as biologic therapies, immunomodulators, or corticosteroids.
Patients should always consult both their gastroenterologist and a qualified medical marijuana physician to determine whether cannabis may be an appropriate addition to their individualized treatment plan.
Medical Cannabis – The Crohn’s & Colitis Foundation, a 501(c)(3) non-profit organization.
References
1. Florida Statutes §381.986, Medical Use of Marijuana (Qualifying Medical Conditions).
2. Naftali T, Mechulam R, Marii A, et al. Cannabis induces a clinical response in patients with Crohn’s disease: A prospective placebo-controlled study. Clinical Gastroenterology and Hepatology. 2013;11(10):1276-1280.
3. Naftali T, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s disease. Digestive Diseases and Sciences. 2017.
4. Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis and cannabis oil for the treatment of Crohn’s disease. Cochrane Database of Systematic Reviews. 2019.
5. Alabed Y, et al. Cannabis use in Crohn’s disease: A systematic review and meta-analysis of randomized controlled trials.Irish Journal of Medical Science. 2025.